BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26022650)

  • 1. Two Cases of Successful Autologous Hematopoietic Stem Cell Harvest after Treatment with Brentuximab Vedotin.
    Kojima M; Ogiya D; Kawai H; Miyamoto M; Ohmachi K; Ogawa Y; Nakamura N; Ando K
    Acta Haematol; 2015; 134(3):181-2. PubMed ID: 26022650
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
    Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
    Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
    Canellos GP; Duggan D; Johnson J; Niedzwiecki D
    J Clin Oncol; 2004 Apr; 22(8):1532-3. PubMed ID: 15084636
    [No Abstract]   [Full Text] [Related]  

  • 4. [Our experience with the treatment of Hodgkin lymphoma patients].
    Illés Á; Garai I; Miltényi Z
    Orv Hetil; 2023 Mar; 164(11):403-410. PubMed ID: 36934353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
    Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
    J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).
    Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M
    Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
    Lopez M
    Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
    [No Abstract]   [Full Text] [Related]  

  • 9. Classical Hodgkin's lymphoma: past, present and future perspectives.
    Eyre TA; King AJ; Collins GP
    Br J Hosp Med (Lond); 2013 Nov; 74(11):612-8. PubMed ID: 24220522
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequencing therapies in Hodgkin lymphoma.
    Phillips EH; Collins GP; Cwynarski K
    Lancet Haematol; 2021 Aug; 8(8):e537-e539. PubMed ID: 34329571
    [No Abstract]   [Full Text] [Related]  

  • 11. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
    Diehl V
    J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
    Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
    Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma.
    Narkhede M; Sarraf Yazdy M; Cheson B
    Expert Rev Hematol; 2018 Oct; 11(10):773-780. PubMed ID: 30139285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marathon running during chemotherapy: where are the limits?
    Dimeo FC
    Onkologie; 2011; 34(5):230. PubMed ID: 21577027
    [No Abstract]   [Full Text] [Related]  

  • 16. Marathon run under chemotherapy: is it possible?
    Bernhörster M; Rosenhagen A; Vogt L; Thiel C; Jäger E; Banzer W
    Onkologie; 2011; 34(5):259-61. PubMed ID: 21577032
    [No Abstract]   [Full Text] [Related]  

  • 17. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006
    [No Abstract]   [Full Text] [Related]  

  • 18. Hematuria--a rare presentation of Hodgkin lymphoma.
    Dembla V; Walker BN; Elkins SL; Files JC
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):788-90; discussion 791-2. PubMed ID: 22252582
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option.
    Canellos GP
    J Clin Oncol; 2005 Jul; 23(21):4574-6. PubMed ID: 15837972
    [No Abstract]   [Full Text] [Related]  

  • 20. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
    Cao H; Yamamoto K; Yang LX; Weber R
    Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.